, Volume 13, Issue 10–11, pp 605–607

4e Recommandations pour la pratique clinique de Nice-St-Paul-de-Vence

Éditorial / Editorial


  1. 1.
    Amalric F (2007) Analyse économique du coût du cancer en France. INCa éditions 2007. http://www.e-cancer.fr
  2. 2.
    Anderson BO, Cazap E, El Saghir NS, et al (2011) Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol 12(4): 387–398PubMedCrossRefGoogle Scholar
  3. 3.
    Aristote (2004) Éthique de Nicomaque. Garnier Flammarion éditionsGoogle Scholar
  4. 4.
    Goldhirsch A, Wood WC, Coates AS, et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the Saint Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8): 1736–1747PubMedCrossRefGoogle Scholar
  5. 5.
    Brouwers MC, Rawski E, Spithoff K, Oliver TK. Inventory of Cancer Guidelines: a tool to advance the guideline enterprise and improve the uptake of evidence. Expert Rev Pharmacoecon Outcomes Res. 2011 Apr;11(2):151–161.PubMedCrossRefGoogle Scholar
  6. 6.
  7. 7.
  8. 8.
    Kerr DJ, Midgley R (2010) Can we treat cancer for a dollar a day? Guidelines for low-income countries. N Engl J Med 363(9): 801–803PubMedCrossRefGoogle Scholar
  9. 9.
    Khayat D (2011) Innovative cancer therapies: putting costs into context. Cancer doi: 10.1002/cncr.26496. [Epub ahead of print]Google Scholar
  10. 10.
    Mergelin F (2010) Du lien d’intérêt au conflit d’intérêts, dossier coordonné par D. Serin et P. Marti (2010) Oncologie 12(11–12): 651–656Google Scholar
  11. 11.
    Mickan S, Burls A, Glasziou P (2011) Patterns of “leakage” in the utilisation of clinical guidelines: a systematic review. Postgrad Med J 87(1032): 670–679PubMedCrossRefGoogle Scholar
  12. 12.
    Namer M (2006) International Consensus-Based Guidelines for Breast Cancer Treatment. ASCO 2006Google Scholar
  13. 13.
    Rawlins MD, Chalkidou K (2011) The opportunity cost of cancer care: a statement from NICE. Lancet Oncol 12 (10): 931–932PubMedCrossRefGoogle Scholar
  14. 14.
    Recommandations pour la pratique clinique en soins de support, Nice-Saint-Paul-de-Vence: et de une ! (2009) Oncologie 11(12): 611Google Scholar
  15. 15.
    Recommandations pour la pratique clinique Nice-Saint-Paul-de-Vence 2011 « Cancers du sein: recommandations et veille bibliographique »; « Soins de support » (2011) Oncologie 13(10–11) et Oncologie 13(12)Google Scholar
  16. 16.
    Recommandations pour la pratique clinique Nice-Saint-Paul-de-Vence 2011, Conseil scientifique (2011) Oncologie 13(10–11)Google Scholar
  17. 17.
    Sant M, Allemani C, Santaquilani M, et al. (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. Eur J Cancer 45(6): 931–991. Epub 2009 Jan 24PubMedCrossRefGoogle Scholar
  18. 18.
    Séroussi B, Bouaud J, Gligorov J, Uzan S (2007) Guidelines et onco-Supporting multidisciplinary staff meetings for guideline-based breast cancer management: a study with OncoDoc2. AMIA Annu Symp Proc 11:656–660Google Scholar
  19. 19.
    Smith TJ, Hillner BE (2011) Bending the cost curve in cancer care. N Engl J Med 364(21): 2060–5PubMedCrossRefGoogle Scholar
  20. 20.
    Wennekes L, Hermens RP, van Heumen K, et al (2008) Possibilities for transborder cooperation in breast cancer care in Europe: a comparative analysis regarding the content, quality and evidence use of breast cancer guidelines. Breast 17(5): 464–471PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2011

Authors and Affiliations

  1. 1.Service d’oncologie médicale, AP-HPhôpital TenonParisFrance
  2. 2.Centre Azuréen de cancérologieMouginsFrance

Personalised recommendations